EPAD

The European Prevention of Alzheimer's Dementia Consortium (EPAD)  is a unique and ground-breaking European initiative to streamline the testing and development of preventative treatments for Alzheimer’s disease.

The largest ever public-private partnership in Alzheimer’s disease research, EPAD combines knowledge and expertise from 39 organisations across multiple sectors. Together, we are developing a platform on which new compounds can be tested in a streamlined and efficient way, delivering more effective, targeted interventions that can slow or stop dementia. 

Jule Duffus, first participant enrolled in dementia study, with Professor Craig Ritchie

Currently Recruiting: No

Visit the EPAD website

This article was published on